Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. (Q40453614)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 2005

Language	Label	Description	Also known as
English	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.	scientific article published on April 2005

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. (English)

1 reference

Europe PubMed Central

20 September 2017

object named as

Jack W Singer

13

0 references

Kenneth C. Anderson

14

object named as

Kenneth C Anderson

1 reference

Europe PubMed Central

20 September 2017

Paul G. Richardson

12

object named as

Paul G Richardson

1 reference

Europe PubMed Central

20 September 2017

6

object named as

Shaji Kumar

1 reference

Europe PubMed Central

20 September 2017

Nikhil V Munshi

11

object named as

Nikhil C Munshi

1 reference

Europe PubMed Central

20 September 2017

5

object named as

Noopur Raje

1 reference

Europe PubMed Central

20 September 2017

Dharminder Chauhan

2

object named as

Dharminder Chauhan

1 reference

Europe PubMed Central

20 September 2017

Kenji Ishitsuka

3

object named as

Kenji Ishitsuka

1 reference

Europe PubMed Central

20 September 2017

1

object named as

Teru Hideshima

1 reference

Europe PubMed Central

20 September 2017

Hiromasa Hideshima

9

object named as

Hiromasa Hideshima

1 reference

Europe PubMed Central

20 September 2017

4

object named as

Hiroshi Yasui

1 reference

Europe PubMed Central

20 September 2017

7

object named as

Klaus Podar

1 reference

Europe PubMed Central

20 September 2017

Constantine S Mitsiades

8

object named as

Constantine Mitsiades

1 reference

Europe PubMed Central

20 September 2017

10

object named as

Lynn Bonham

1 reference

Europe PubMed Central

20 September 2017

language of work or name

0 references

publication date

1 April 2005

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

24

1 reference

Europe PubMed Central

20 September 2017

19

1 reference

Europe PubMed Central

20 September 2017

3121-3129

1 reference

Europe PubMed Central

20 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.onc.1208522

0 references

Randomized trial experience of the Intergroupe Francophone du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Lysophosphatidic acid acyltransferase-β: a novel target for induction of tumour cell apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

NF-kappa B as a therapeutic target in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Novel therapeutic approaches for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Mitochondrial permeability transition: a common pathway to necrosis and apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

The emerging role of lysophosphatidic acid in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Platelet-collagen interaction: is GPVI the central receptor?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208522

21 January 2018

Identifiers

10.1038/SJ.ONC.1208522

1 reference

Europe PubMed Central

20 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40453614&oldid=1856569210"